Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors

NCT02671435 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02671435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02671435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Durvalumab and Monalizumab in Adult Subjects With Select Advanced Solid Tumors
Lead sponsor
MedImmune LLC
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 22, 2016
Completion date
July 30, 2027
Enrollment
383 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors